4.5 Article

Prevalence of obstructive coronary artery disease and prognosis in patients with stable symptoms and a zero-coronary calcium score

期刊

出版社

OXFORD UNIV PRESS
DOI: 10.1093/ehjci/jex037

关键词

coronary artery calcification; stable angina; coronary CT angiography; coronary artery disease; prognosis

向作者/读者索取更多资源

Aims CT calcium scoring (CTCS) and CT cardiac angiography (CTCA) are widely used in patients with stable chest pain to exclude significant coronary artery disease (CAD). We aimed to resolve uncertainty about the prevalence of obstructive coronary artery disease and long-term outcomes in patients with a zero-calcium score (ZCS). Methods and results Consecutive patients with stable cardiac symptoms referred for CTCS or CTCS and CTCA from chest pain clinics to a tertiary cardiothoracic centre were prospectively enrolled. In those with a ZCS, the prevalence of obstructive CAD on CTCA was determined. A follow-up for all-cause mortality was obtained from the NHS tracer service. A total of 3914 patients underwent CTCS of whom 2730 (69.7%) also had a CTCA. Half of the patients were men (50.3%) with a mean age of 56.9 years. Among patients who had both procedures, a ZCS was present in 52.2%, with a negative predictive value of 99.5% for excluding >= 70% stenosis on CTCA. During a mean followup of 5.2 years, the annual event rate was 0.3% for those with ZCS compared with 1.2% for CS >= 1. The presence of non-calcified atheroma on CTCA in patients with ZCS did not affect the prognostic value (P = 0.98) Conclusion In patients with stable symptoms and a ZCS, obstructive CAD is rare, and prognosis over the long-term is excellent, regardless of whether non-calcified atheroma is identified. A ZCS could reliably be used as a 'gatekeeper' in this patient cohort, obviating the need for further more expensive tests.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Cardiac & Cardiovascular Systems

Spontaneous Reperfusion in Patients with Transient ST-Elevation Myocardial Infarction-Prevalence, Importance and Approaches to Management

Mohamed Farag, Marta Peverelli, Nikolaos Spinthakis, Ying X. Gue, Mohaned Egred, Diana A. Gorog

Summary: This review discusses the therapeutic management dilemma presented by patients with transient ST-elevation myocardial infarction (STEMI) or spontaneous resolution (SpR) of ST-segment elevation. The potential mechanisms underlying SpR, its relation to clinical outcomes, and the management options for transient STEMI patients with a focus on immediate versus early percutaneous coronary intervention are explored. Available data suggest that deferring angiography and revascularization within 24-48 hours in these patients is reasonable and may lead to similar or better outcomes compared to immediate angiography. Further randomized trials are needed to determine the optimal pharmacological and invasive strategies for this patient population.

CARDIOVASCULAR DRUGS AND THERAPY (2023)

Review Cardiac & Cardiovascular Systems

Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock JACC Review Topic of the Week

Christophe Vandenbriele, Deepa J. Arachchillage, Pascal Frederiks, Gennaro Giustino, Diana A. Gorog, Mario Gramegna, Stefan Janssens, Bart Meyns, Amin Polzin, Mara Scandroglio, Benedikt Schrage, Gregg W. Stone, Guido Tavazzi, Thomas Vanassche, Pascal Vranckx, Dirk Westermann, Susanna Price, Alaide Chieffo

Summary: There is growing interest in the use of mechanical circulatory support for patients with cardiogenic shock, but the delicate balance between bleeding and thrombosis poses challenges for patient outcomes. This article presents an anti-Factor Xa/activated partial thromboplastin time-guided anticoagulation algorithm and discusses the monitoring pitfalls of heparin in critically ill patients, aiming to guide physicians in standardizing anticoagulation treatment to reduce device-related morbidity and mortality.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

Article Medicine, General & Internal

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly, Keith A. A. Fox, Jonas Oldgren, W. Schuyler Jones, Diana A. Gorog, Vaclav Durdil, Thomas Viethen, Christoph Neumann, Hardi Mundl, Manesh R. Patel

Summary: This study compared the incidence of bleeding in patients with atrial fibrillation between Asundexian and apixaban, showing that Asundexian resulted in lower rates of bleeding compared with standard dosing of apixaban.

LANCET (2022)

Review Hematology

Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper

Diana A. Gorog, Ying X. Gue, Tze-Fan Chao, Laurent Fauchier, Jose Luis Ferreiro, Kurt Huber, Stavros V. Konstantinidis, Deirdre A. Lane, Francisco Marin, Jonas Oldgren, Tatjana Potpara, Vanessa Roldan, Andrea Rubboli, Dirk Sibbing, Hung-Fat Tse, Gemma Vilahur, Gregory Y. H. Lip

Summary: This article summarizes the consensus on bleeding risk assessments in patients with atrial fibrillation (AF) and venous thromboembolism (VTE), including bleeding risk factors, definitions, and the consideration of patient values and preferences in balancing bleeding against thromboembolism risks.

THROMBOSIS AND HAEMOSTASIS (2022)

Editorial Material Cardiac & Cardiovascular Systems

Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease Does Less Mean More?

Ying X. Gue, Diana A. Gorog, Gregory Y. H. Lip

JAMA CARDIOLOGY (2022)

Editorial Material Cardiac & Cardiovascular Systems

Factor XIa Inhibition: Is It a Novel Alternative Antithrombotic Strategy for High-Risk ACS Patients?

Ying X. Gue, Diana A. Gorog, Gregory Y. H. Lip

CIRCULATION (2022)

Article Cardiac & Cardiovascular Systems

Biomarkers of Thrombotic Status Predict Spontaneous Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction

Rahim Kanji, Ying X. Gue, Vassilios Memtsas, Neil H. Spencer, Diana A. Gorog

Summary: Spontaneous reperfusion in ST-segment elevation myocardial infarction (STEMI) patients is related to decreased thrombotic profile and improved outcomes.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Review Hematology

Comparison of De-escalation of DAPT Intensity or Duration in East Asian and Western Patients with ACS Undergoing PCI: A Systematic Review and Meta-analysis

Diana A. Gorog, Visvesh Jeyalan, Rafaella I. L. Markides, Eliano P. Navarese, Young-Hoon Jeong, Mohamed Farag

Summary: There are differences in bleeding risk between East Asians and non-East Asians in acute coronary syndrome patients undergoing dual antiplatelet therapy (DAPT). In East Asians, reducing the intensity or duration of DAPT can minimize bleeding risk. In non-East Asians, reducing the intensity of DAPT may increase the risk of ischemia. Reducing the duration of DAPT can reduce bleeding risk without significant impact on ischemic risk.

THROMBOSIS AND HAEMOSTASIS (2023)

Article Cardiac & Cardiovascular Systems

The Use and Efficacy of FFR-CT Real-World Multicenter Audit of Clinical Data With Cost Analysis

Tarun K. Mittal, Sandeep S. Hothi, Vinod Venugopal, John Taleyratne, David O'Brien, Kazi Adnan, Joban Sehmi, Georgios Daskalopoulos, Aparna Deshpande, Sara Elfawal, Vinoda Sharma, Rajai A. Shahin, Mengshi Yuan, Dominik Schlosshan, Andrew Walker, Saif-El-Dean Abdel Rahman, Imran Sunderji, Sidhesh Wagh, Jocelyn Chow, Mohammed Masood, Sumeet Sharma, Sharad Agrawal, Chary Duraikannu, Elisa Mcalindon, Saeed Mirsadraee, Edward D. Nicol, Andrew D. Kelion

Summary: In this study, the use of FFR-CT in clinical practice was audited against England's guidance, and its diagnostic accuracy and cost were assessed. The study found that FFR-CT had a low positive predictive value, making it potentially more expensive than conventional stress imaging strategies.

JACC-CARDIOVASCULAR IMAGING (2023)

Article Critical Care Medicine

Antigoagulation in the ICU: a future for contact pathway inhibition?

Charlotte J. Van Edom, Diana A. Gorog, Christophe Vandenbriele

INTENSIVE CARE MEDICINE (2023)

Article Cardiac & Cardiovascular Systems

De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis

Diana A. Gorog, Jose Luis Ferreiro, Ingo Ahrens, Junya Ako, Tobias Geisler, Sigrun Halvorsen, Kurt Huber, Young-Hoon Jeong, Eliano P. Navarese, Andrea Rubboli, Dirk Sibbing, Jolanta M. Siller-Matula, Robert F. Storey, Jack W. C. Tan, Jurrien M. ten Berg, Marco Valgimigli, Christophe Vandenbriele, Gregory Y. H. Lip

Summary: Dual antiplatelet therapy (DAPT) reduces the risk of ischaemic events but increases bleeding risk in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Strategies to reduce bleeding include de-escalation of DAPT intensity or abbreviation of DAPT duration, which both require individual assessment of ischaemic and bleeding risks.

NATURE REVIEWS CARDIOLOGY (2023)

Letter Cardiac & Cardiovascular Systems

REPLY: Functional Testing vs FFR-CT in Intermediate Stenosis

Tarun K. Mittal, Sandeep S. Hothi, Edward D. Nicol, Andrew D. Kelion

JACC-CARDIOVASCULAR IMAGING (2023)

Article Hematology

Measuring Thrombus Stability at High Shear, Together With Thrombus Formation and Endogenous Fibrinolysis: First Experience Using the Global Thrombosis Test 3 (GTT-3)

Rahim Kanji, Joshua Leader, Vassilios Memtsas, Diana A. Gorog

Summary: Thrombus formation in severely stenosed arteries is mainly initiated by high shear activation of platelets, and soluble platelet agonists have a secondary role in thrombus growth and stability. Conventional platelet function tests only evaluate the soluble agonist-dependent pathway of aggregation. The Global Thrombosis Test (GTT) simulates thrombus formation in whole blood under high shear flow and measures occlusive thrombus formation time and spontaneous thrombolysis. The GTT-3 model provides additional assessment of thrombus stability and can be used to evaluate the impact of antithrombotic medications on thrombus stability at high shear.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2023)

Article Medicine, General & Internal

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Peter W. Horby, Jonathan R. Emberson, Marion Mafham, Mark Campbell, Leon Peto, Guilhenne Pessoa-Amorim, Enti Spata, Natalie Staplin, Catherine Lowe, David R. Chadwick, Christopher Brightling, Richard Stewart, Paul Collini, Abdul Ashish, Christopher A. Green, Ben Prudon, Timothy Felton, Anthony Kerry, J. Kenneth Baillie, Maya H. Such, Jeremy Day, Saul N. Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Richard Haynes, Martin J. Landray

Summary: This study evaluated the use of baricitinib in the treatment of patients hospitalized with COVID-19. The results showed that baricitinib significantly reduced the risk of death, although the effect size was slightly smaller than previous trials. Overall evidence suggests that JAK inhibitors can reduce mortality in hospitalized COVID-19 patients by about 20%.

LANCET (2022)

Article Medicine, General & Internal

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W. Horby, Marion Mafham, Leon Peto, Mark Campbell, Guilherme Pessoa-Amorim, Enti Spata, Natalie Staplin, Jonathan R. Emberson, Benjamin Prudon, Paul Hine, Thomas Brown, Christopher A. Green, Rahuldeb Sarkar, Purav Desai, Bryan Yates, Tom Bewick, Simon Tiberi, Tim Felton, J. Kenneth Baillie, Maya H. Bitch, Lucy C. Chappell, Saul N. Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, David M. Weinreich, Richard Haynes, Martin J. Landray

Summary: This study evaluated the efficacy and safety of the combination therapy of casirivimab and imdevimab in patients hospitalized with COVID-19. The results showed that this combination therapy reduced the 28-day mortality rate in patients without detectable antibodies to SARS-CoV-2 infection at baseline, but not in those with detectable antibodies.

LANCET (2022)

暂无数据